Cytokinetics, Incorporated (NASDAQ:CYTK) Q4 2025 Earnings Call Transcript
Cytokinetics, Incorporated (NASDAQ:CYTK) Q4 2025 Earnings Call Transcript February 24, 2026Cytokinetics, Incorporated misses on earnings expectations.
Cytokinetics Inc (CYTK)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Bayforest Capital Theodoros Tsagaris | 1,093 | $72,040 | 0.08% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $8.57 | 6,000 | $51,426.60 | 6,250 | 2019-11-19 | Filing | |
| $9.52 | 8,506 | $80,934.59 | 499,312 | 2019-12-11 | Filing | |
| $9.52 | 49,804 | $473,885.06 | 2,861,622 | 2019-12-11 | Filing | |
| $9.52 | 60,103 | $571,880.05 | 3,617,776 | 2019-12-11 | Filing | |
| $9.40 | 15,030 | $141,282.00 | 490,806 | 2019-12-10 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $66.02 | 7,449 | $491,782.98 | 58,555 | 2026-04-15 | Filing | |
| $65.38 | 7,500 | $490,350.00 | 415,330 | 2026-04-15 | Filing | |
| $64.75 | 1,000 | $64,750.00 | 153,902 | 2026-04-07 | Filing | |
| $65.21 | 3,500 | $228,235.00 | 153,902 | 2026-04-07 | Filing | |
| $66.63 | 7,500 | $499,725.00 | 422,830 | 2026-04-01 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 300,762 | $19,823,223 | 0.52% | |
| 2. | 202,673 | $13,358,177 | 1.89% | |
| 3. | 21,505 | $1,417,395 | 0.22% | |
| 4. | 12,730 | $839,034 | 0.16% | |
| 5. | 9,150 | $603,076 | 0.02% |
News See All
Cytokinetics, Incorporated (CYTK) Poised for Market Share Gain with Myqorzo in Cardiac Myosin Space
Cytokinetics (NASDAQ:CYTK) is one of the best debt-free mid-cap stocks to buy according to hedge funds. On February 4, B.
10 Best Debt-Free Mid-Cap Stocks to Buy According to Hedge Funds
Mid-cap stocks are poised for an impressive run heading into the US midterm election.
Truist Notes Operational Investments For Cytokinetics, Incorporated (CYTK) to Support Short-Term Growth
TheFly reported on February 3 that Truist raised its price target on CYTK to $92 from $84 and maintained a Buy rating. The company revised its model ahead of its Q4 results to account for the impact...
15 Innovative Healthcare Stocks to Buy According to Analysts
Over the last two years, artificial intelligence has propelled global financial markets into a boom, with stocks reaching all-time highs.
Cytokinetics, Incorporated (CYTK): A Bull Case Theory
We came across a bullish thesis on Cytokinetics, Incorporated on Valueinvestorsclub.com by Bohr. In this article, we will summarize the bulls’ thesis on CYTK.
Cytokinetics, Incorporated (NASDAQ:CYTK) Q3 2025 Earnings Call Transcript
Operator: Thank you for standing by, and welcome to the Cytokinetics Q3 2025 Earnings Conference Call. This call is being recorded and all participants will be in a listen-only mode.
Cytokinetics (CYTK) Drops on $650-Million Debt Issuance
In a statement, Cytokinetics, Inc. (NASDAQ:CYTK) said it aimed to raise $650 million from the offer, an increase from the $550 million targeted initially.
Cytokinetics (CYTK) Rockets 40.45% as Aficamten Results Promising
Cytokinetics snapped a two-day losing streak on Tuesday, soaring 40.45 percent to close at $49.62 apiece as investors cheered promising results from its study of Aficamten, its drug candidate for the ...
Citi Lowers Cytokinetics (CYTK) PT to $77 Due to Uneventful Q2 2025 Earnings
Cytokinetics Incorporated (NASDAQ:CYTK) is one of the best upside stocks to invest in now.
Hedge Fund Resource Center